

10/583,468



STN-Structure Search
11/11/08

=> d ibib abs hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:15873 CAPLUS
DOCUMENT NUMBER: 144:108216
TITLE: Preparation of amido compounds as inhibitors of
11-β-hydroxysteroid dehydrogenase type 1
(11βHSD1) and antagonists of the
mineralocorticoid receptor (MR)
INVENTOR(S): Yao, Wengqing; Xu, Meizhong; Zhang, Colin; Agrios,
Konstantinos; Metcalf, Brian; Zhuo, Jincong
PATENT ASSIGNEE(S): Incyte Corporation, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002349	A1	20060105	WO 2005-US22411	20050623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005258248	A1	20060105	AU 2005-258248	20050623
CA 2571258	A1	20060105	CA 2005-2571258	20050623
US 2006009471	A1	20060112	US 2005-159724	20050623
EP 1758582	A1	20070307	EP 2005-762543	20050623
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1988908	A	20070627	CN 2005-80020965	20050623
IN 2006KN03601	A	20070615	IN 2006-KN3601	20061201
KR 2007024639	A	20070302	KR 2006-727142	20061222
NO 2007000372	A	20070308	NO 2007-372	20070119
PRIORITY APPLN. INFO.:			US 2004-582556P	P 20040624
			US 2004-639179P	P 20041222
			WO 2005-US22411	W 20050623

OTHER SOURCE(S): MARPAT 144:108216
GI



AB The title compds. I [Cy = (un)substituted (hetero)aryl, (hetero)cycloalkyl; L = absent, (CR₁₃R₁₄)_m, (CR₁₃R₁₄)_nO(CR₁₃R₁₄)_p, etc.; R₁, R₂ = (un)substituted alkyl; R₃-R₁₂ = H, W₁X₁Y₁Z₁; or R₃ and R₄ together or R₅ and R₆ together or R₇ and R₈ together or R₉ and R₁₀ together or R₁₁ and R₁₂ together form 4-20 membered cycloalkyl or (un)substituted heterocycloalkyl; or R₃ and R₁₂ together or R₃ and R₁₀ together or R₃ and R₈ together or R₅ and R₁₀ together or R₇ and R₁₂ together form (un)substituted alkylene bridge; R₁₃, R₁₄ = H, halo, alkyl, etc.; W₁ = absent, alkylenyl, O, etc.; X₁ = absent, alkylenyl, aryl, etc.; Y₁ = absent, O, S, etc.; Z₁ = H, halo, CN, etc.; m = 1-4; n = 0-3; p = 0-3; q = 0-2; with the provisos] which are inhibitors of 11-β hydroxysteroid dehydrogenase type 1 and antagonists of the mineralocorticoid receptor (MR), were prepared. Thus, reacting 2-(4-chlorophenyl)-2-methylpropanoic acid with (1S)-1,2,3,4-tetrahydroisoquinolin-1-ylmethanol in the presence of BOP and N-methylmorpholine in DMF afforded (1S)-II. The compds. I can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxysteroid dehydrogenase type 1 and/or diseases associated with aldosterone excess. The pharmaceutical composition comprising the compound

I is disclosed.

IT 872985-55-2P 872986-34-0P 872986-36-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of amido compds. as inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and antagonists of the mineralocorticoid receptor (MR))

RN 872985-55-2 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-(4-chlorophenoxy)-2-methyl-1-oxopropyl)-, (1'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-34-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[1,1-dimethyl-2-oxo-2-[(1R)-3-oxospiro[isobenzofuran-1(3H),3'-pyrrolidin]-1'-yl]ethoxy]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-36-2 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-methyl-1-oxo-2-[4-(1-piperazinyl)phenoxy]propyl]-, (1R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 872985-48-3P 872985-49-4P 872985-50-7P

872985-51-8P 872985-52-9P 872985-53-0P

872985-54-1P 872985-56-3P 872985-57-4P

872986-15-7P 872986-19-1P 872986-21-5P

872986-23-7P 872986-25-9P 872986-27-1P

872986-38-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amido compds. as inhibitors of 11- β -hydroxysteroid dehydrogenase type 1 (11 β HSD1) and antagonists of the mineralocorticoid receptor (MR))


RN 872985-48-3 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-(4-cyanophenoxy)-2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 872985-49-4 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-(4-chlorophenoxy)-2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 872985-50-7 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-[4-(cyanomethyl)phenoxy]-2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 872985-51-8 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidine], 1'-(2-[4-(cyanomethyl)phenoxy]-2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 872985-52-9 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-methyl-1-oxo-2-[4-(2-pyridinyl)phenoxy]propyl)- (CA INDEX NAME)




RN 872985-53-0 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 872985-54-1 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidine]-, 1'-(2-[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 872985-56-3 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-(2,4-dichlorophenoxy)-2-methyl-1-oxopropyl)-, (1'R)- (9CI) (CA INDEX NAME)

10/583,468


Absolute stereochemistry.



RN 872985-57-4 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(3,4-dichlorophenoxy)-2-methyl-1-oxopropyl]-, (1'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-15-7 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-methyl-1-oxo-2-phenoxypropyl)-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-19-1 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-[2-(3,5-dichlorophenoxy)-2-methyl-1-oxopropyl]-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-21-5 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-[4-chloro-3-(trifluoromethyl)phenoxy]-2-methyl-1-oxopropyl)-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-23-7 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-(4-chloro-3-fluorophenoxy)-2-methyl-1-oxopropyl)-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-25-9 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-(4-chloro-2-methylphenoxy)-2-methyl-1-oxopropyl)-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-27-1 CAPLUS

CN Spiro[isobenzofuran-1(3H),3'-pyrrolidin]-3-one, 1'-(2-methyl-1-oxo-2-[4-(trifluoromethyl)phenoxy]propyl)-, (1R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 872986-38-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[1,1-dimethyl-2-oxo-2-[(1R)-3-oxospiro[isobenzofuran-1(3H),3'-pyrrolidin]-1'-yl]ethoxy]phenyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:588965 CAPLUS



DOCUMENT NUMBER: 143:115452

TITLE: Preparation of tricyclic spiropiperidines as

INVENTOR(S) : modulators of chemokine receptor activity
 Hossain, Nafizal; Ivanova, Svetlana
 PATENT ASSIGNEE(S) : AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061499	A1	20050707	WO 2004-SE1938	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303735	A1	20050707	AU 2004-303735	20041220
AU 2004303735	B2	20070920		
CA 2548494	A1	20050707	CA 2004-2548494	20041220
EP 1699791	A1	20060913	EP 2004-809111	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
BR 2004017036	A	20070206	BR 2004-17036	20041220
CN 1918160	A	20070221	CN 2004-80042013	20041220
JP 2007515476	T	20070614	JP 2006-546906	20041220
MX 2006PA07025	A	20060831	MX 2006-PA7025	20060619
US 2007099945	A1	20070503	US 2006-583468	20060620
IN 2006MN00848	A	20070518	IN 2006-MN848	20060718
NO 2006003355	A	20060922	NO 2006-3355	20060719
PRIORITY APPLN. INFO.:			SE 2003-3541	A 20031222
			WO 2004-SE1938	W 20041220

OTHER SOURCE(S) : CASREACT 143:115452; MARPAT 143:115452
 GI




AB Title compds. I [$m = 0-4$; $R1$ = halo, CN, OH, etc.; X = bond, CH_2 and Y = bond, CH_2 provided that X , Y do not both simultaneously represent bond, CH_2 ; $n = 0-2$; $R2$ = halo, alkyl, haloalkyl; $q = 0-1$; $p = 0-2$; $R3$ = halo, amino, carboxyl, etc.; $R4$ = H, alkyl, haloalkyl, halo; $a = 0-2$ provided that p and a are not both 0; $R5$ = (un)saturated 5-10-membered ring system] are prepared. For instance, II is prepared in 4 steps from 5-methoxy-2-nitrophenol, (S)-oxiran-2-ylmethanol, and 5-chlorospiro[3H-benzofuran-2,4'-piperidine] (preparation given). I are modulators of chemokine receptor activity [no data] and useful for the treatment of, e.g., rheumatoid arthritis.

IT 857264-51-8P, N-[2-[3-Amino-2-(spiro[3H-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl]acetamide
 RL: BYP (Byproduct); PREP (Preparation)
 (preparation of tricyclic spiropiperidines as modulators of chemokine receptor activity)

RN 857264-51-8 CAPLUS


CN Acetamide, N-[2-(3-amino-2-spiro[benzofuran-2(3H),4'-piperidin]-1'-ylpropoxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



IT 857264-43-8P, N-[2-[3-Amino-2-(5-chlorospiro[3H-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy]-4-methoxyphenyl]acetamide
 RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of tricyclic spiropiperidines as modulators of chemokine receptor activity)

RN 857264-43-8 CAPLUS

CN Acetamide, N-[2-[3-amino-2-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)propoxy]-4-methoxyphenyl]- (CA INDEX NAME)



IT 857264-79-0P, 5-Chloro-2-[2-chloro-3-(5-chlorospiro[3H-benzofuran-2,4'-piperidin]-1'-yl)propoxy]-4-[(4-methoxybenzyl)oxy]benzoic acid trifluoroacetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of tricyclic spiropiperidines as modulators of chemokine receptor activity)


RN 857264-79-0 CAPLUS

CN Benzoic acid, 5-chloro-2-[2-chloro-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)propoxy]-4-[(4-methoxyphenyl)methoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 857264-78-9


CMF C30 H30 Cl3 N O6



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:41477 CAPLUS

DOCUMENT NUMBER: 140:93937

TITLE: Preparation of tricyclic spiropiperidines or spiropyrrolidines useful against disorders affected by modulation of chemokine receptors

INVENTOR(S): Hossain, Nafizal; Ivanova, Svetlana;
 Mensonides-Harsema, Marguerite

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.



SOURCE: PCT Int. Appl., 281 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005295	A1	20040115	WO 2003-SE1185	20030707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492122	A1	20040115	CA 2003-2492122	20030707
AU 2003243122	A1	20040123	AU 2003-243122	20030707
EP 1521757	A1	20050413	EP 2003-762957	20030707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012560	A	20050510	BR 2003-12560	20030707
CN 1675218	A	20050928	CN 2003-819146	20030707
JP 2005537255	T	20051208	JP 2004-519472	20030707
NZ 537259	A	20060831	NZ 2003-537259	20030707
CN 1974574	A	20070606	CN 2006-10143556	20030707
IN 2004DN04014	A	20070427	IN 2004-DN4014	20041216
ZA 2005000024	A	20060222	ZA 2005-24	20050103
MX 2005PA00278	A	20050331	MX 2005-PA278	20050104
US 2005245741	A1	20051103	US 2005-520699	20050107
NO 2005000635	A	20050331	NO 2005-635	20050204
PRIORITY APPLN. INFO.:			SE 2002-2133	A 20020708
			CN 2003-819146	A3 20030707
			WO 2003-SE1185	W 20030707

OTHER SOURCE(S): MARPAT 140:93937
 GI



AB The invention provides tricyclic spiropiperidines or spiropyrrolidines (shown as I; variables defined below; e.g. II), processes for their preparation, pharmaceutical compns. containing them and their use in therapy for

disorders affected by modulation of chemokine receptors (no data). For I: m is 0-4; each R1 = halogen, cyano, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or sulfonamido; either X = a bond, -CH2-, -O- or -C(O)- and Y = a bond, -CH2-, -O- or -C(O)-, or X and Y together = -CH:CHMe- or -CMe:CH-, and Z = a bond, -O-, -NH- or -CH2-, provided that only one of X, Y and Z can be a bond at any one time and provided that X and Y do not both simultaneously = -O- or -C(O)-. N = 0-2; each R2 = halogen or C1-C6 alkyl; q = 0-1; R3 = -NHC(O)R10, -C(O)NR11R12 or -COOR12a; R4, R5, R6, R7 and R8 = H or a C1-C6 alkyl group; t = 0-2; each R9 = halogen, cyano, hydroxy, carboxy, C1-C6 alkoxy, C1-C6 alkoxy carbonyl, C1-C6 haloalkyl, or C1-C6 alkyl; addnl. details are given in the claims. Methods of preparation are claimed and >200 example preps. are included. For example, II was prepared in 2 steps starting from N-(2-hydroxyphenyl)acetamide, ((2S)-oxiran-2-yl)methyl and Cs₂CO₃ in DMF to give N-[2-[((2S)-oxiran-2-yl)methoxy]phenyl]acetamide as an intermediate, which was reacted with 5-chloro-3H-spiro[1-benzofuran-2,4'-piperidine] in EtOH to give II.

IT 644968-87-6P 644969-01-7P 644969-11-9P

644969-20-0P 644969-46-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of tricyclic spiropiperidines or spiropyrrolidines useful against disorders affected by modulation of chemokine receptors)

RN 644968-87-6 CAPLUS


CN Acetamide, N-[2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-4-hydroxyphenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 644968-86-5

CMF C24 H29 Cl N2 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/583, 468

RN 644969-01-7 CAPLUS

CN Acetamide, N-[2-[(2S)-2-hydroxy-2-methyl-3-spiro[isobenzofuran-1(3H),4'-piperidin]-1'-ylpropoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 644969-11-9 CAPLUS

CN Benzamide, 2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-N-cyclopropyl-4-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 644969-20-0 CAPLUS


CN Benzamide, 2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-4-hydroxy-N-methyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 644969-19-7

CMF C24 H29 Cl N2 O5


Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2RN 644969-46-0 CAPLUS
CN Benzamide, 2-[(2S)-3-(5-chlorospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-N-cyclopropyl-4-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

IT 644969-14-2P 644969-23-3P 644969-47-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic spiroperidines or spiropyrrolidines useful against disorders affected by modulation of chemokine receptors)
RN 644969-14-2 CAPLUS
CN Benzamide, 2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-N-cyclopropyl-4-[(4-methoxyphenyl)methoxy]- (CA INDEX NAME)

10/583,468


Absolute stereochemistry.



RN 644969-23-3 CAPLUS

CN Benzamide, 2-[(2S)-3-(5-chlorospiro[benzofuran-2(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-4-[(4-methoxyphenyl)methoxy]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 644969-47-1 CAPLUS

CN Benzamide, 2-[(2S)-3-(5-chlorospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl)-2-hydroxy-2-methylpropoxy]-N-cyclopropyl-4-[(4-methoxyphenyl)methoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10/583,468



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:43:59 ON 11 JAN 2008)

FILE 'REGISTRY' ENTERED AT 11:44:10 ON 11 JAN 2008

L1 STRUCTURE uploaded
L2 2 S L1
L3 65 S L1 FULL


FILE 'CAPLUS' ENTERED AT 11:45:10 ON 11 JAN 2008

L4 3 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C, N, X

Structure attributes must be viewed using STN Express query preparation.

=>